Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4KH2

Crystal structure of human alpha-L-iduronidase complex with 2-deoxy-2-fluoro-alpha-L-idopyranosyluronic acid fluoride

Summary for 4KH2
Entry DOI10.2210/pdb4kh2/pdb
Related4JXO 4JXP 4KGJ 4KGL
DescriptorAlpha-L-iduronidase, S,R MESO-TARTARIC ACID, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (11 entities in total)
Functional Keywordsglycoside hydrolase family 39, tim barrel, beta sandwich, fibronectin iii domain, glycosaminoglycans, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceHomo sapiens (human)
Cellular locationLysosome: P35475
Total number of polymer chains2
Total formula weight145151.97
Authors
Bie, H.,Yin, J.,He, X.,Kermode, A.R.,Goddard-Borger, E.D.,Withers, S.G.,James, M.N.G. (deposition date: 2013-04-29, release date: 2013-09-18, Last modification date: 2024-10-09)
Primary citationBie, H.,Yin, J.,He, X.,Kermode, A.R.,Goddard-Borger, E.D.,Withers, S.G.,James, M.N.
Insights into mucopolysaccharidosis I from the structure and action of alpha-L-iduronidase.
Nat.Chem.Biol., 9:739-745, 2013
Cited by
PubMed Abstract: Mucopolysaccharidosis type I (MPS I), caused by mutations in the gene encoding α-L-iduronidase (IDUA), is one of approximately 70 genetic disorders collectively known as the lysosomal storage diseases. To gain insight into the basis for MPS I, we crystallized human IDUA produced in an Arabidopsis thaliana cgl mutant. IDUA consists of a TIM barrel domain containing the catalytic site, a β-sandwich domain and a fibronectin-like domain. Structures of IDUA bound to iduronate analogs illustrate the Michaelis complex and reveal a (2,5)B conformation in the glycosyl-enzyme intermediate, which suggest a retaining double displacement reaction involving the nucleophilic Glu299 and the general acid/base Glu182. Unexpectedly, the N-glycan attached to Asn372 interacts with iduronate analogs in the active site and is required for enzymatic activity. Finally, these IDUA structures and biochemical analysis of the disease-relevant P533R mutation have enabled us to correlate the effects of mutations in IDUA to clinical phenotypes.
PubMed: 24036510
DOI: 10.1038/nchembio.1357
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.36 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon